PegBio Co., Ltd.

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.

產業

Biotechnology

部門

Healthcare

總部

CN

執行長

Min Xu

上市以來

2025年5月27日

僱員

58